Bladder-sparing management for high grade noninvasive urothelial carcinoma of the prostate

• Published in: Urologic oncology Vol. 43; no. 9; pp. 521.e1 - 521.e8
• Main Authors: Martin, Alexander C., McElree, Ian M., Mott, Sarah L., Hougen, Helen Y., Steinberg, Ryan L., O'Donnell, Michael A., Packiam, Vignesh T.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2025
• Subjects: Adjuvants, Immunologic - administration & dosage; Administration, Intravesical; Aged; Antineoplastic Agents - administration & dosage; BCG; BCG Vaccine - administration & dosage; Bladder cancer; Carcinoma in Situ - mortality; Carcinoma in Situ - pathology; Carcinoma in Situ - therapy; Cystectomy; Docetaxel; Docetaxel - administration & dosage; Follow-Up Studies; Gemcitabine; Gemcitabine - administration & dosage; Humans; Kaplan-Meier Estimate; Male; Neoplasm Grading; Organ Sparing Treatments - methods; Organ Sparing Treatments - mortality; Proportional Hazards Models; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Prostatic Neoplasms - therapy; Prostatic urethral; Retrospective Studies; Survival Rate; Treatment Outcome; Urinary Bladder - pathology; Urothelium - pathology; Prostatic urethral; Gemcitabine; Bladder cancer; Docetaxel; BCG
• ISSN: 1078-1439; 1873-2496; 1873-2496
• DOI: 10.1016/j.urolonc.2025.04.007

•Intravesical therapy can be effective for prostatic urethral urothelial carcinoma.•No statistically significant difference between Gem/Doce and BCG therapy.•No predictive factors identified associated with high grade recurrence.•Most high-grade recurrence occurs within 6 months, moderate progressio...